Salman Dahlia, Swinden Julian, Peron Jean-Marie R, Barton Stephen, Nabhani-Gebara Shereen
a Researcher in Oncology Pharmacy Practice-Pharmaceutical Analysis, School of Pharmacy and Chemistry, Faculty of Science , Engineering and Computing, Kingston University-London, Kingston upon Thames , London , UK.
b School of Pharmacy and Chemistry, Faculty of Science , Engineering and Computing, Kingston University-London, Kingston upon Thames , London , UK.
Expert Rev Anticancer Ther. 2016;16(1):123-30. doi: 10.1586/14737140.2016.1121106.
It is important for sarcoma patients to receive the correct dose of Mesna as an adjuvant with ifosfamide to reduce the risk of hemorrhagic cystitis. This paper describes a study conducted to evaluate the physicochemical stability of Mesna for injection formulation over 14 days.
Mesna samples (n = 4, 20 mg/ml) were incubated in glass vials at 37 + 0.5ºC. Mesna concentrations were determined by liquid chromatography-mass spectrometry (LC-MS/MS), and nuclear magnetic resonance spectroscopy (NMR) was used to detect degradation products. Evaporative losses and pH were also monitored.
Our results differed from those published in existing literature. Both LC-MS/MS and NMR indicated that Mesna was unstable. The mean percentage decrease in Mesna concentration was 40% by day 14 of the analysis. The presence of Mesna's dimer Dimesna was detected on day 0 and its concentration increased over time. Dimesna was the only by-product identified.
Both LC-MS/MS and NMR analyses confirmed the instability of Mesna and its conversion into Dimesna.
